Monday, May 3, 2021
OCGN - Ocugen Extremely Strong in a Hot Vaccine Market
Ocugen closed a $100 Million Offering last week and has continued to trade higher. The chart is incredibly strong with a large scale expanding pattern. OCGN is wide open to the upside. Price is very aggressively channelling higher. Any comparable with a viable Covid-19 vaccine is trading at far greater prices. The United Stated is in a mass vaccination program currently. Everybody is thinking and talking about vaccines, therefore, the vaccine market is red hot at this time. India is experiencing a Covid outbreak that is rampant and will overwhelm the hospital system shortly...
Daily
Subscribe to:
Post Comments (Atom)
Bought OCGN $14.10.
ReplyDelete"MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. It is notable that the Brazilian variant, B1.128.2, contains the E484K mutation that was found in New York.
ReplyDeleteIn the ICMR studies, COVAXIN-vaccinated sera effectively neutralized several SARS-CoV-2 variants (B.1.617 (India, double mutant), B.1.1.7 (United Kingdom), B.1.1.28 (Brazil P2), and heterologous strain) in an in-vitro plaque reduction neutralization assay. These studies suggest that COVAXIN vaccination may be effective against multiple SARS-CoV-2 variants."
News gapping OCGN higher this morning. The gap is likely to fill actually, but a lot of strength regardless.
ReplyDeleteI look forward to the inferms as covid vaccines revive the dead
ReplyDeletesc,
ReplyDeletenew chart---new page-----are you still holding UVXY--from the previous chart ---???
Yes
DeleteWith India in this situation fear is going to come in
DeleteSold OCGN $15.40.
ReplyDeleteShould be better entries soon.
DeleteOCGN hasn't even had a decent down day on this run. I think it is coming soon. Taking profits seems to be the right choice.
ReplyDeleteSC,
ReplyDeleteAre you holding through the UVXY r/s? Does it affect your targets at all?
The volatility is coming but what makes this a challenge for UVXY is that the VIX futures are in contango.
Deletehttp://vixcentral.com/
The rs doesn't bother me but contango is a battle. I'm going to review.
DeleteSc
ReplyDeleteSo you have any charts on cryptos ?
We're getting closer to launching a bitcoin etf in the US. This is going to be an important event.
DeleteOil update coming also. Looking good.
ReplyDeleteSold UVXY $4.56
ReplyDeleteLook to enter again soon. After split.
DeleteDo you know when they are supposed to split. I can't seem to find anything. Just this article on https://sixfigureinvesting.com/2014/01/uvxy-reverse-split/
DeleteSC,
DeleteDo you have a price target? Under $40 for uvxy?
UVXY reverse split tomorrow
DeleteLet's update charts after split tomorrow.
Deletesc,
ReplyDeleteVIX is at 20 again--???
Yellin--speaks Friday
Good Day to-short?
yep
ReplyDeletesc,
ReplyDeletewhere are you looking to buy OCGN back ---what level?
I'm waiting for the dust to settle. OCGN 50 day is at $8.67.
DeleteHold off on OCGN until XBI covers gap at 115....its going to do it in next 2 days by looks of it...ultimately XBI could go to 95....I would load up huge there....
ReplyDeleteLABD to short it on way down, should accelerate in final move to 38
Yes selling off. XBI not oversold yet. I see the previous high for OCGN $18 in February also coincides with the high in XBI in February.
DeleteYes the whole complex is selling off. I see Novavax NVAX is getting hit too. News sparked some selling:
ReplyDelete"U.S. backs waiving patent protections for Covid vaccines, citing global health crisis"
"Stocks of major pharmaceutical companies that have produced vaccines, including Moderna, BioNTech and Pfizer, dropped sharply after news of the potential waivers first broke. Pfizer ended its trading day flat, while Moderna lost 6.1%; Johnson & Johnson shed a modest 0.4%."
DeleteSome confusion on UVXY split. Proshares put out press release on April 22 showing UVXY 10 for 1 reverse split but the dates are wrong on the announcement.
ReplyDeleteSo we assume a split is coming but not sure which day.
New chart posted!
ReplyDelete